CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

Shared decision-making forms an increasingly important part of the expert consultation for athletes with genetic heart ...

Although sedentary behavior may be an evolutionarily selected trait, it is still important to try to be physically active, says a new study conducted at the , Finland.

Although sedentary behavior may be an evolutionarily selected trait, it is still important to try to be physically active, says a new study. Researchers have shown for the first time that genetic ...

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Although sedentary behavior may be an evolutionarily selected trait, it is still important to try to be physically active, ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the United ...

Experimental Lilly Drug Cuts Genetic Heart Disease Risk Factor by 94% in Trial By Julie Steenhuysen CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly ...